Alkene epoxidation catalyzed by cytochrome P450 BM-3 139-3

Edgardo T. Farinas,† Miguel Alcalde‡ and Frances Arnold*

Division of Chemistry and Chemical Engineering, California Institute of Technology, 210-41, Pasadena, CA 91125, USA

Received 20 June 2003; accepted 17 October 2003

Abstract—We recently reported conversion of cytochrome P450 BM-3, a medium-chain (C₁₂ – C₁₈) fatty acid monooxygenase, into a highly efficient alkane hydroxylase by directed evolution [Nat. Biotechnol. 2002, 20, 1135]. P450 BM-3 mutant 139-3 exhibited high activity towards a variety of fatty acid and alkane substrates, including C₃ – C₈ alkanes. We report here that mutant 139-3 is also active on benzene, styrene, cyclohexene, 1-hexene, and propylene. Benzene is converted to phenol, while styrene is converted to styrene oxide. Propylene oxidation generates only propylene oxide, but cyclohexene oxidation produces a mixture of cyclohexene oxide (85%) and 2-cyclohexene-1-ol (15%), and 1-hexene is converted to the allylic hydroxylation product, 1-hexene-3-ol. Initial rates of NADPH oxidation for 139-3 in the presence of the substrates greatly (17- to 100-fold) surpass the wild-type in all cases. However, NADPH consumption is only partially coupled to product formation (14–79%). This cytochrome P450 epoxidation catalyst is a suitable starting point for further evolution to improve coupling and activity.

1. Introduction

Catalyzing a wide range of oxidative reactions under mild conditions in aqueous solutions, cytochrome P450 monoxygenases (P450s) are interesting potential 'green' catalysts.¹ It has been shown that many of their limitations, including poor activities towards non-natural substrates,²–⁹ limited stability,¹⁰ inability to withstand organic solvent,¹² and even their cofactor requirements¹¹,¹³ can be improved by protein engineering, particularly directed evolution.

This group recently described directed evolution of the highly active, soluble fatty acid hydroxylase P450 BM-3 for selective alkane oxidation.⁹ Five generations of random mutagenesis/recombination and screening transformed P450 BM-3 into an efficient alkane hydroxylase, which we named 139-3. The evolved gene contained 13 nucleotide base substitutions in the region coding for the heme domain, resulting in 11 amino acid changes. Mutant 139-3 displayed higher turnover rates than any reported enzyme for the (subterminal) hydroxylation of alkanes with chain lengths between C₄ and C₈ (3600 min⁻¹ for hexane). It also exhibited ~2-fold higher initial activity for lauric and palmitic acid, which are already good substrates for the wild-type. Here we report that the broadly-active 139-3 mutant is also a good epoxidation catalyst. Much more active than the wild-type P450 BM-3, mutant 139-3 is a convenient platform for further directed evolution to optimize epoxidation of specific substrates.

Scheme 1. Substrates oxidized by BM-3 variant 139-3 and the corresponding products. For benzene, styrene, cyclohexene, or 1-hexene oxidations, the reaction mixture contained enzyme, substrate, and methanol in potassium phosphate buffer. For propylene oxidation, the buffer was first saturated with propylene. Reactions were initiated by addition of NADPH, and products were analyzed by GC/MS.
The activity of BM-3 mutant 139-3 was evaluated against the substrates shown in Scheme 1 and Table 1. Benzene was converted to phenol, presumably via epoxidation of the aromatic ring, with a maximum initial rate of NADPH oxidation of 200 mol/min/mol enzyme. The wild-type enzyme in the presence of benzene shows no NADPH consumption above background (Table 1). For styrene, cyclohexene, 1-hexene, and propylene, the maximum rates of NADPH oxidation by 139-3 also greatly surpassed those for wild-type (between 17- and 100-fold) (Table 1). Styrene and propylene oxidation by 139-3 yielded styrene oxide and propylene oxide, respectively. Cyclohexene oxidation yielded cyclohexene oxide (85%) and 2-cyclohexene-1-ol (15%).

The sole product of 1-hexene oxidation was the allylic hydroxylation product, 1-hexene-3-ol. This was not unexpected, since wild-type P450 BM-3 preferentially oxidizes o-unsaturated fatty acids at the allylic position, and the corresponding terminal epoxide is not formed. It has been proposed that the structure of the BM-3 substrate binding pocket prevents terminal oxidation. The pocket resembles a long funnel at the end of which a small hydrophobic pocket sequesters the substrate terminus, rendering it unavailable for oxidation. The selectivity also reflects the different C–H bond strengths: the o secondary C–H bond (ΔH°f = 83 kcal/mol) is weaker than the o–secondary C–H bond (ΔH°f = 98 kcal/mol).

NADPH oxidation is not necessarily an accurate measure of P450 catalytic activity, because electron equivalents from NADPH can be diverted to produce reduced oxygen species (H₂O or H₂O₂). Using NADPH as a limiting reagent, the reported initial rate of CPO-catalyzed styrene epoxidation is 288 min⁻¹, with only 2% coupling to styrene oxide formation (1.1 min⁻¹). Mutant 139-3, despite its not being 100% coupled, has an initial rate of styrene oxide formation of 385 min⁻¹ and is more active than any reported P450 for this reaction.

Caldariomyces fumago chloroperoxidase (CPO) performs some P450-like oxygen insertion reactions, including epoxidation. The reported initial rate of CPO-catalyzed styrene epoxidation is 288 min⁻¹. CPO utilizes peroxide in the catalytic cycle and does not require expensive cofactors such as NADPH or additional electron transfer proteins. However, CPO is not functionally expressed in Escherichia coli, presumably due to the bacterium’s inability to do the processing or post-translational modifications to CPO that occur in the natural, fungal host. Recombinant CPO can be expressed in C. fumago, but the fungus does not provide a convenient transformation or expression system for rational protein design or directed evolution experiments. In contrast, P450 BM-3 and its mutants, including 139-3, are soluble and easily expressed in E. coli. Cirino and Arnold have recently shown that P450 BM-3 heme domain alone can be evolved to use the peroxide shunt pathway, much like CPO. Thus it should be possible to engineer mutants of the P450 heme domain that catalyze epoxidation, using peroxide.

Chiral epoxides are useful synthetic intermediates for the pharmaceutical and chemical industries, and P450s are potential asymmetric epoxidation catalysts. However, slow reaction rates and low expression yields have hampered the synthetic utility of enzymes. For the oxidation of styrene by

---

Table 1. Products, turnover rates, and coupling during oxidation catalyzed by cytochrome P450 BM-3 mutant 139-3.

<table>
<thead>
<tr>
<th>Substrate</th>
<th>Products</th>
<th>Maximum initial rate</th>
<th>Coupling (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benzene</td>
<td>Phenol (100%)</td>
<td>200±64 (10)</td>
<td>14</td>
</tr>
<tr>
<td>Styrene</td>
<td>Styrene oxide (100%)</td>
<td>1100±87 (17±15)</td>
<td>35</td>
</tr>
<tr>
<td>Cyclohexene</td>
<td>Cyclohexene oxide (85%)</td>
<td>1200±130 (0)</td>
<td>79</td>
</tr>
<tr>
<td>1-Hexene</td>
<td>1-Hexene-1-ol (100%)</td>
<td>1300±160 (60±8)</td>
<td>22</td>
</tr>
<tr>
<td>Propylene</td>
<td>Propylene oxide (100%)</td>
<td>700±62 (40±31)</td>
<td>nd</td>
</tr>
</tbody>
</table>

a The product yields and distributions were determined by gas chromatography/mass spectrometry as described in Section 4.
b Maximum initial rates are given in mmol NADPH consumed/min/mmol P450.
c nd Not determined.
d The value in the parenthesis represents the ratio of product formed/totaled product.

e The value in the parenthesis represents the maximum initial rate for the wild-type.

---

2. Results and discussion

The activity of BM-3 mutant 139-3 was evaluated against the substrates shown in Scheme 1 and Table 1. Benzene was converted to phenol, presumably via epoxidation of the aromatic ring, with a maximum initial rate of NADPH oxidation of 200 mol/min/mol enzyme. The wild-type enzyme in the presence of benzene shows no NADPH consumption above background (Table 1). For styrene, cyclohexene, 1-hexene, and propylene, the maximum rates of NADPH oxidation by 139-3 also greatly surpassed those for wild-type (between 17- and 100-fold) (Table 1). Styrene and propylene oxidation by 139-3 yielded styrene oxide and propylene oxide, respectively. Cyclohexene oxidation yielded cyclohexene oxide (85%) and 2-cyclohexene-1-ol (15%).

The sole product of 1-hexene oxidation was the allylic hydroxylation product, 1-hexene-3-ol. This was not unexpected, since wild-type P450 BM-3 preferentially oxidizes o-unsaturated fatty acids at the allylic position, and the corresponding terminal epoxide is not formed. It has been proposed that the structure of the BM-3 substrate binding pocket prevents terminal oxidation. The pocket resembles a long funnel at the end of which a small hydrophobic pocket sequesters the substrate terminus, rendering it unavailable for oxidation. The selectivity also reflects the different C–H bond strengths: the o secondary C–H bond (ΔH°f = 83 kcal/mol) is weaker than the o–secondary C–H bond (ΔH°f = 98 kcal/mol).

NADPH oxidation is not necessarily an accurate measure of P450 catalytic activity, because electron equivalents from NADPH can be diverted to produce reduced oxygen species (H₂O or H₂O₂). Using NADPH as a limiting reagent, the reported initial rate of CPO-catalyzed styrene epoxidation is 288 min⁻¹, with only 2% coupling to styrene oxide formation (1.1 min⁻¹). Mutant 139-3, despite its not being 100% coupled, has an initial rate of styrene oxide formation of 385 min⁻¹ and is more active than any reported P450 for this reaction.

P450s are known to epoxidize a broad range of alkenes and arenes, with rates ranging from 1 min⁻¹ for microsomal proteins to 3200 min⁻¹ for bacterial enzymes. Using styrene for comparison, P450cam from Pseudomonas putida is reported to have an initial rate of NADH consumption of 51 min⁻¹, with only 2% coupling to styrene oxide formation (1.1 min⁻¹). Mutant 139-3, despite its not being 100% coupled, has an initial rate of styrene oxide formation of 385 min⁻¹ and is more active than any reported P450 for this reaction.

Caldariomyces fumago chloroperoxidase (CPO) performs some P450-like oxygen insertion reactions, including epoxidation. The reported initial rate of CPO-catalyzed styrene epoxidation is 288 min⁻¹. CPO utilizes peroxide in the catalytic cycle and does not require expensive cofactors such as NADPH or additional electron transfer proteins. However, CPO is not functionally expressed in Escherichia coli, presumably due to the bacterium’s inability to do the processing or post-translational modifications to CPO that occur in the natural, fungal host. Recombinant CPO can be expressed in C. fumago, but the fungus does not provide a convenient transformation or expression system for rational protein design or directed evolution experiments. In contrast, P450 BM-3 and its mutants, including 139-3, are soluble and easily expressed in E. coli. Cirino and Arnold have recently shown that P450 BM-3 heme domain alone can be evolved to use the peroxide shunt pathway, much like CPO. Thus it should be possible to engineer mutants of the P450 heme domain that catalyze epoxidation, using peroxide.

Chiral epoxides are useful synthetic intermediates for the pharmaceutical and chemical industries, and P450s are potential asymmetric epoxidation catalysts. However, slow reaction rates and low expression yields have hampered the synthetic utility of enzymes. For the oxidation of styrene by
P450cam, P450terp from *Pseudomonas* sp., and P450 BM-3, the ratios of S/R styrene oxide produced are 12:88, 83:17, and 40:60, respectively. Mutant 139-3, which was evolved to hydroxylate alkanes, shows no enantioselectivity in this reaction (S/R styrene oxide = 50:50). With a suitable high throughput screen, however, enantioselectivity is also a good target for optimization by directed evolution.

3. Conclusion

The broadly-active laboratory-evolved cytochrome P450 BM-3 mutant 139-3 is far more active than the wild-type enzyme as a catalyst for epoxidation reactions. The activity of wild-type P450 BM-3 on the substrates investigated here is too low to monitor in high throughput and therefore too low for improvement by directed evolution. The evolved enzyme is a suitable parent for further directed evolution to improve rates and coupling efficiency, both of which can be optimized by appropriate changes in the catalyst. It is also possible to modify enantioselectivity. This relatively stable, efficient, and easily-produced enzyme has potential as an epoxidation catalyst.

4. Experimental

All chemicals were purchased from commercial sources and used as received.

4.1. Expression of P450 BM-3 mutant 139-3

The mutant P450 BM-3 gene was cloned behind the double *tac* promoter of the expression vector pCWori. For enzyme production, supplemented terrific broth medium (500 ml) was inoculated with 0.5 ml of an overnight culture of *E. coli* DH5α containing the expression plasmid. After shaking for 10 h at 35 °C, δ-aminolevulinic acid hydrochloride (ALA, 0.5 mM) was added, and expression was induced by the addition of isopropyl-β-D-thiogalactoside (IPTG, 1 mM). The cells were cultivated for 30 h at 30 °C. The enzyme was purified following published procedures, and the enzyme concentration was determined from the CO-difference spectra.

4.2. Determination of maximum initial rates of oxidation

The mutant was purified and quantified as described above. The initial rate of oxidation was determined as described. A typical reaction solution contained enzyme (1.0 ml, 1.0 μM) in potassium phosphate buffer (0.1 M, pH 8.0), substrate (2 mM), and methanol (1% v/v). The reaction was initiated by the addition of NADPH (200 μM). After completion of the reaction, the solution was extracted once with CHCl₃ (300 μl) containing 1-hexanol (0.5 mM) as an internal standard. The organic layer was analyzed by GC/MS using a Hewlett Packard 6890 gas chromatograph coupled to a Hewlett Packard 5973 mass selective detector. The GC was fitted with an Agilent Technologies Innowax column (30 m x 0.25 mm with a film thickness of 0.25 μm). The conditions are as follows: (i) 35 °C for 5 min, (ii) 35–200 °C at 20 °C/min, (iii) isothermic at 200 °C for 5 min. Authentic standards were used to identify the retention times and to prepare standard curves. Products were further verified by matching the fragmentation distributions with a database in the software provided with the instrument. Chiral resolution of styrene oxide was determined using a GC fitted with a chiral column (25x0.25 mm Hydrodex β-6 TBDM, Macherey-Nagel), and the conditions are as follows: (i) 100 °C for 10 min, (ii) 100–170 °C at 20 °C/min, (iii) isothermic at 170 °C for 6 min, (iv) 170–100 °C at 20 °C/min, (v) isothermic 100 °C for 1 min. Percent coupling is determined from the ratio of moles of product formed to the moles of NADPH added to the reaction. NADPH was the limiting reagent, and the substrate concentration was 10X that of NADPH to ensure complete consumption of NADPH. The total product formed was determined by GC/MS, as described above. The concentration of NADPH was determined spectrophotometrically by measuring the absorbance at 340 nm (ε = 6210 M⁻¹ cm⁻¹) of the stock solution. The amount of H₂O₂ generated by the reaction was determined using the 2,2'-azino-bis[3-ethylbenzothiazoline-6-sulfonic acid]/horseradish peroxidase (ABTS/HRP) assay according to published procedures.

Acknowledgements

The authors thank Dr Nathan Dalleska for assistance with the GC/MS and Dr Bernhard Hauer for the chiral analysis of styrene oxide. This research is funded by the National Science Foundation.

References and notes